Cite

    Janku, F., Abdul-Karim, R., Azad, A., Bendell, J., Gan, H., Sen, S., Tan, T., Wang, J., Marina, N., Baker, L., Ma, L., Mooney, J., Luo, D., Leveque, J., Milla, M., & Meniawy, T. (n.d.). preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. European journal of cancer, 138, S11–. http://access.bl.uk/ark:/81055/vdc_100120048175.0x000022